Q1 2025 Financial Results & Business Update Nasdaq: OABI May 8, 2025 1 Disclaimer 2 Information regarding partnered products and programs comes from reports or information publicly released by our partners and have not been independently verified by OmniAb. For our definitions of "active partners," "active programs," "active clinical programs and approved products" and "approved products", see "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on For ...

OmniAb, Inc. (OABI) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.13 per share when it actually produced a loss of $0.12, delivering a surprise of 7.69%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.OmniAb, Inc., which belongs to the Zacks Medic ...

OmniAb (OABI) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to OmniAb, Inc. First Quarter twenty twenty five Financial Results and Business Update Conference Call. At this time, all participants are in listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the call over to Cord Gustafson, OmniAb, Inc. Chief Financial Officer. You may begin. Speaker1 Thank you, operat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Pe ...

Exhibit 99.1 Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (May 8, 2025) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. "We have started the year with robust deal flow, including both platform and asset-based deals. Our business remains strong as our diversified pipeline of partner programs is progressing with recent and expected new clinical entrants and dat ...

Core Insights - VERAXA Biotech AG has announced a co-discovery alliance with OmniAb, Inc. to develop a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors, combining their respective technologies for enhanced therapeutic discovery [1][2] - The collaboration is part of VERAXA's strategy to drive innovation through strategic partnerships, marking its second major initiative in six months [2] - Under the agreement, VERAXA will utilize OmniAb's transgenic antibody discovery solutions to source high-quality human antibody leads and will be responsible for preclinical validation of the bsADC lead candidate [2] Company Overview - VERAXA is focused on the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs and other innovative formats, leveraging transformative technologies and quality-by-design principles [3] - The company was founded on scientific breakthroughs from the European Molecular Biology Laboratory, emphasizing its commitment to pioneering life science research [3] Business Combination - On April 22, 2025, VERAXA entered into a definitive business combination agreement with Voyager Acquisition Corp., which is expected to lead to VERAXA becoming a publicly traded company on NASDAQ [4] - Voyager Acquisition Corp. aims to revolutionize the healthcare sector through strategic mergers and business combinations, supported by a team with extensive expertise in investing and medical innovation [5]

OmniAb, Inc. (NASDAQ:OABI) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Kripa Devarakonda - Truist Securities Operator Good afternoon and welcome to OmniAb Inc's Fourth Quarter and Full Year 2024 Financial Results and Business Update Conference call. At this time, all participants are in a listen-only mode. Following the pre ...

Core Viewpoint - OmniAb, Inc. reported a quarterly loss of $0.12 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.13, and improved from a loss of $0.14 per share a year ago, indicating a positive earnings surprise of 7.69% [1] Financial Performance - The company posted revenues of $10.8 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 18.21%, and showing significant growth from $4.82 million in the same quarter last year [2] - Over the last four quarters, OmniAb has surpassed consensus EPS estimates two times and has also topped consensus revenue estimates two times [2] Stock Performance - OmniAb shares have declined approximately 10.5% since the beginning of the year, compared to a decline of 3.5% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $6.16 million, and for the current fiscal year, it is -$0.46 on revenues of $47.55 million [7] Industry Outlook - The Medical - Drugs industry, to which OmniAb belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook as the top 50% of Zacks-ranked industries tend to outperform the bottom 50% by more than 2 to 1 [8]

Q4 and Full Year 2024 Financial Results & Business Update Nasdaq: OABI March 18, 2025 1 Disclaimer 2 We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, including our financial guidance for 2025, business strategy, our expectations regarding the application of, and the rate and degree of market acceptance of, o ...

Financial Performance - The company has incurred losses on an as-reported basis for the last several years and may not generate sufficient revenue to achieve and maintain profitability[104]. - For the years ended December 31, 2024 and 2023, the company's revenue was $26.4 million and $34.2 million, respectively, with net losses of $62.0 million and $50.6 million[132]. - The company has incurred net losses historically and expects to continue incurring losses as it invests in research and development[132]. - The company may need to raise additional capital to fund operations and achieve goals, with existing cash and cash equivalents expected to meet needs for at least the next 12 months[125]. - The company’s ability to forecast future revenues may be limited due to its reliance on partners for the development and commercialization of therapeutic candidates[110]. - The company relies on a limited number of partners for revenue, and the loss of any significant partner could adversely impact its business[130]. Market and Competitive Landscape - The life sciences and biotech platform technology market is highly competitive, with significant competition in therapeutic antibody discovery[145]. - The company must continue to invest in its platform and technology to maintain a competitive position in a rapidly changing industry[153]. - The company’s platform must demonstrate advantages over legacy technologies to maintain market acceptance, which is critical for its business[118]. - The company faces challenges in marketing its solutions due to its pricing model, which is structured to capture downstream revenues[148]. Regulatory and Compliance Risks - The company currently faces limited direct regulation by the FDA, but future oversight could increase compliance costs and operational uncertainty[181]. - Compliance with healthcare laws and regulations may expose the company and its partners to civil penalties and reputational harm[182]. - The evolving landscape of data privacy laws, including the GDPR, could impose significant fines up to €20 million or 4% of annual global revenue for breaches[186]. - The regulatory framework for AI Technologies is rapidly evolving, potentially impacting the company's operations and compliance costs[189]. - New laws regulating AI Technologies are expected to enter into force in the U.S. and EU, which may require significant resource allocation for compliance[190]. Intellectual Property Risks - The company may incur substantial litigation costs if it fails to protect its intellectual property, which could impair its competitive position[201]. - Changes in patent law could diminish the value of patents, impacting the company's ability to protect its technology[209]. - The company cannot ensure that its pending patent applications will lead to issued patents, which could impact its ability to maintain a competitive advantage[236]. - The company may face challenges in acquiring or licensing necessary technologies on acceptable terms, which could hinder future commercialization efforts[220]. - The company relies on trade secrets and confidentiality agreements to protect its proprietary information, but there is uncertainty regarding the effectiveness of these measures[235]. Operational Risks - The company relies on third parties for hosting mouse and rat colonies and supplying laboratory equipment, which may impact its research and development efforts if these parties do not perform satisfactorily[104]. - Information technology systems are critical for operations, and any failure could harm business performance and reputation[165]. - The company’s facilities are vulnerable to damage from disasters, which could jeopardize research and development efforts[172]. - The company is exposed to risks of employee misconduct, which could lead to legal sanctions and significant reputational harm[256]. Stock and Securities Risks - The market price of the company's common stock is likely to be highly volatile, and significant sales of its securities could cause stock prices to decline[108]. - The company has issued warrants for an aggregate of 19,012,156 shares of common stock, with an exercise price of $11.50 per share, which may lead to dilution for existing shareholders[293]. - The company may face significant costs and management distractions from potential securities class action litigation due to share price volatility[269]. - The company is classified as an emerging growth company and smaller reporting company, allowing it to take advantage of reduced reporting requirements until it surpasses $1.235 billion in total annual gross revenue or $700 million in market value[284]. Capital and Funding Risks - The company may consider raising additional capital for strategic investments or acquisitions, even if it believes it has sufficient funds for current operations[127]. - The company faces potential disruptions to its operations due to pandemics or public health emergencies, which could delay research and development activities and increase operating costs[266]. - Market, interest, and credit risks may reduce the value of investments, with potential liquidity shortages due to recent financial institution closures[194]. Miscellaneous Risks - The company may incur liability, including litigation exposure, penalties, and fines, due to potential security breaches affecting personal information[180]. - The company faces risks from security breaches and data loss, which could compromise sensitive information and disrupt operations[177]. - The company is subject to complex export and import laws, with potential criminal liability for violations that could adversely affect its business[259].